Q3 2021 13F Holders as of 9/30/2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
19.3M
-
Number of holders
-
200
-
Total 13F shares, excl. options
-
16.4M
-
Shares change
-
+459K
-
Total reported value, excl. options
-
$2.29B
-
Value change
-
+$68.6M
-
Put/Call ratio
-
0.39
-
Number of buys
-
85
-
Number of sells
-
-94
-
Price
-
$139.32
Significant Holders of LIGAND PHARMACEUTICALS INC - Common Stock (LGND) as of Q3 2021
239 filings reported holding LGND - LIGAND PHARMACEUTICALS INC - Common Stock as of Q3 2021.
LIGAND PHARMACEUTICALS INC - Common Stock (LGND) has 200 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 16.4M shares
of 19.3M outstanding shares and own 85.03% of the company stock.
Largest 10 shareholders include BlackRock Inc. (2.73M shares), VANGUARD GROUP INC (1.72M shares), JANUS HENDERSON GROUP PLC (1.46M shares), WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC (1.38M shares), STATE STREET CORP (918K shares), MACQUARIE GROUP LTD (645K shares), VILLERE ST DENIS J & CO LLC (564K shares), Chicago Capital, LLC (440K shares), Stephens Investment Management Group LLC (410K shares), and RICE HALL JAMES & ASSOCIATES, LLC (374K shares).
This table shows the top 200 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.